睿知中国医院研究地图
候选清单

即将招募淋巴瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07615283,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Centrally confirmed histopathological/cytologic diagnosis of PTCL with the following subtypes:

    入选标准第 2 条

  3. Met the criteria of relapsed/refractory lymphoma: Relapsed lymphoma was defined as relapsed lymphoma after achieving complete response (CR) or partial response(PR)after initial therapy. Refractory is defined as having an evaluation of progressive disease (PD) after 2 cycles, or stable disease (SD) after 4 cycles of a previous systemic therapy regimen.

    入选标准第 8 条

    Thyroid stimulating hormone (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) within the normal range ±10% (Note: non-autoimmune causes of abnormal TSH, FT3 and FT4 can be maintained in the normal range after replacement treatment of hypothyroidism can be enrolled).

    入选标准第 21 条

    Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of medication; Effective contraception should be used from the time of informed consent until 6 months after the last dose of study drug.

    入选标准第 23 条

    Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 3 years prior to the first dose of study drug (patients who received allo-HSCT > 3 years prior to the first dose of study drug and currently have no active graft-versus-host disease [GVHD] are eligible to enroll);

    排除标准第 5 条

    Currently participating in another clinical study, or less than 4 weeks elapsed from the end of treatment in a previous clinical study to the planned start of study treatment;

    排除标准第 8 条

    Less than 3 months elapsed since the last dose of prior treatment with any immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4).

    排除标准第 10 条

    Underwent major surgery within 28 days, or received radiotherapy within 90 days prior to the start of study treatment;

    排除标准第 15 条

    Patients with active chronic hepatitis B or active hepatitis C. Hepatitis B SurfaceAntigen (HBsAg) or hepatitis B core Antibody (HBcAb) or Hepatitis C Virus (HCV) during the screening period HCV) antibody positive patients must be further tested for Hepatitis B Virus (HBV) DNA (no more than 2500 copies /mL or 500 IU/mL) and HCV RNA (no more than the lower limit of detection of the assay), Enrollment in the trial occurred after the exclusion of patients with active hepatitis B or hepatitis C infection requiring treatment. Hepatitis B virus (HBV) carriers, medically stable hepatitis B (DNA > 2500 copies /mL or 500IU/mL) and cured hepatitis C patients are eligible for enrollment.

    排除标准第 18 条

  4. ECOG performance status score: 0-2;

    入选标准第 10 条

  5. Blood routine: absolute neutrophil count (ANC) ≥ 1.0×109/L;

    入选标准第 13 条

    platelet count (PLT) ≥ 60×109/L;

    入选标准第 14 条

    hemoglobin (HGB) ≥ 8.0 g/dL;

    入选标准第 15 条

    white blood cell (WBC) ≥ 3.5×109/L;

    入选标准第 16 条

    Renal function: serum creatinine (Cr) ≤1.5×ULN.or creatinine clearance (CrCl) ≥ 40 mL/min (calculated using the Cockcroft-Gault formula);

    入选标准第 17 条

    serum total bilirubin (TBIL) ≤1.5× upper limit of normal value ;

    入选标准第 18 条

    alanine aminotransferase (ALT) and aspartate transferase (AST) ≤2.5×ULN ;

    入选标准第 19 条

    Coagulation function: International Normalized Ratio (INR) ≤1.5 × ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) ≤1.5×ULN (unless the subject is receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).

    入选标准第 20 条

  6. There must be at least one measurable or evaluable lesion that meets the Lugano 2014 criteria for lymphoma: Measurable lesion: Nodal lesions with major diameter greater than 1.5cm and minor diameter greater than 1.0cm as assessed by PET/CT or Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI); Or the length of extranodal lesions >1.0cm; 2)Evaluable lesions: PET-CT showed increased uptake in lymph nodes or extranodal regions (higher than liver) and imaging features consistent with lymphoma;

    入选标准第 9 条

  7. Diagnosis of another malignancy within the past 5 years, except for malignancies treated with curative intent, including basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast, or carcinoma in situ of the cervix.

    排除标准第 13 条

    Received systemic anti-tumor therapy within 28 days prior to the start of study treatment, including chemotherapy, immunotherapy, and biological therapy (tumor vaccines, cytokines, or growth factors to control cancer);

    排除标准第 14 条

    Patients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired immunodeficiency syndrome;

    排除标准第 17 条

  8. Pregnant or lactating women;

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07615283,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years old,regardless of gender;
  2. Centrally confirmed histopathological/cytologic diagnosis of PTCL with the following subtypes:
  3. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS);
  4. Systemic anaplastic large cell lymphoma (ALK+ and ALK-);
  5. Follicular helper T (TFH) cell lymphoma of lymph nodes, including angioimmunoblastic, follicular, NOS;
  6. NKTCL
  7. and any other PTCL subtypes deemed by the investigator to be eligible for inclusion.
  8. Met the criteria of relapsed/refractory lymphoma: Relapsed lymphoma was defined as relapsed lymphoma after achieving complete response (CR) or partial response(PR)after initial therapy. Refractory is defined as having an evaluation of progressive disease (PD) after 2 cycles, or stable disease (SD) after 4 cycles of a previous systemic therapy regimen.
  9. There must be at least one measurable or evaluable lesion that meets the Lugano 2014 criteria for lymphoma: Measurable lesion: Nodal lesions with major diameter greater than 1.5cm and minor diameter greater than 1.0cm as assessed by PET/CT or Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI); Or the length of extranodal lesions >1.0cm; 2)Evaluable lesions: PET-CT showed increased uptake in lymph nodes or extranodal regions (higher than liver) and imaging features consistent with lymphoma;
  10. ECOG performance status score: 0-2;
  11. Expected survival time ≥3 months;
  12. Have adequate organ and bone marrow function, defined as follows(The patients had not received granulocyte growth factor, platelet transfusion, or red blood cell transfusion within 14 days before the examination):
  13. Blood routine: absolute neutrophil count (ANC) ≥ 1.0×109/L;
  14. platelet count (PLT) ≥ 60×109/L;
  15. hemoglobin (HGB) ≥ 8.0 g/dL;
  16. white blood cell (WBC) ≥ 3.5×109/L;
  17. Renal function: serum creatinine (Cr) ≤1.5×ULN.or creatinine clearance (CrCl) ≥ 40 mL/min (calculated using the Cockcroft-Gault formula);
  18. serum total bilirubin (TBIL) ≤1.5× upper limit of normal value ;
  19. alanine aminotransferase (ALT) and aspartate transferase (AST) ≤2.5×ULN ;
  20. Coagulation function: International Normalized Ratio (INR) ≤1.5 × ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) ≤1.5×ULN (unless the subject is receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).
  21. Thyroid stimulating hormone (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) within the normal range ±10% (Note: non-autoimmune causes of abnormal TSH, FT3 and FT4 can be maintained in the normal range after replacement treatment of hypothyroidism can be enrolled).
  22. Capable of understanding the study procedures and voluntarily signing a written informed consent form (ICF).;
  23. Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of medication; Effective contraception should be used from the time of informed consent until 6 months after the last dose of study drug.

排除标准:Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Patients with hemophagocytic lymphohistiocytosis;
  3. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.
  4. History of allogeneic organ transplantation;
  5. Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 3 years prior to the first dose of study drug (patients who received allo-HSCT > 3 years prior to the first dose of study drug and currently have no active graft-versus-host disease [GVHD] are eligible to enroll);
  6. Known allergy or hypersensitivity to the study drugs or their related metabolites;
  7. Uncontrolled active infection;
  8. Currently participating in another clinical study, or less than 4 weeks elapsed from the end of treatment in a previous clinical study to the planned start of study treatment;
  9. Planned autologous hematopoietic stem cell transplantation (auto-HSCT);
  10. Less than 3 months elapsed since the last dose of prior treatment with any immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4).
  11. Active autoimmune disease that required systemic treatment within the past 2 years (hormone replacement therapy is not considered systemic treatment, e.g., type 1 diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy, or adrenal/pituitary insufficiency requiring only physiologic doses of corticosteroids). Patients with an autoimmune disease that did not require systemic treatment within the past 2 years are eligible to enroll;
  12. Required systemic treatment with corticosteroids or other immunosuppressive agents for any condition within 14 days prior to the start of study treatment (except for topical or short-term use of corticosteroids, or corticosteroids used for non-autoimmune conditions such as delayed-type hypersensitivity caused by contact allergens);
  13. Diagnosis of another malignancy within the past 5 years, except for malignancies treated with curative intent, including basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the breast, or carcinoma in situ of the cervix.
  14. Received systemic anti-tumor therapy within 28 days prior to the start of study treatment, including chemotherapy, immunotherapy, and biological therapy (tumor vaccines, cytokines, or growth factors to control cancer);
  15. Underwent major surgery within 28 days, or received radiotherapy within 90 days prior to the start of study treatment;
  16. Received live vaccines within 28 days prior to the start of study treatment (excluding attenuated influenza vaccines);
  17. Patients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired immunodeficiency syndrome;
  18. Patients with active chronic hepatitis B or active hepatitis C. Hepatitis B SurfaceAntigen (HBsAg) or hepatitis B core Antibody (HBcAb) or Hepatitis C Virus (HCV) during the screening period HCV) antibody positive patients must be further tested for Hepatitis B Virus (HBV) DNA (no more than 2500 copies /mL or 500 IU/mL) and HCV RNA (no more than the lower limit of detection of the assay), Enrollment in the trial occurred after the exclusion of patients with active hepatitis B or hepatitis C infection requiring treatment. Hepatitis B virus (HBV) carriers, medically stable hepatitis B (DNA > 2500 copies /mL or 500IU/mL) and cured hepatitis C patients are eligible for enrollment.
  19. Active tuberculosis (TB);
  20. Uncontrolled fungal or bacterial infections;
  21. Known history of alcohol or substance abuse;
  22. Uncontrolled comorbidities, including but not limited to symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, active peptic ulcer, or bleeding disorders;
  23. History of interstitial lung disease or non-infectious pneumonitis (subjects with a history of asymptomatic drug-induced or radiation-induced non-infectious pneumonitis are eligible for enrollment);
  24. QTcF interval > 450 msec, unless secondary to bundle branch block;
  25. History of psychiatric disorders;
  26. Severe concomitant diseases that, in the judgment of the investigator, would compromise patient safety or interfere with the patient's ability to complete the study;
  27. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for inclusion in this study.

引自 ClinicalTrials.gov, NCT07615283, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07615283,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07615283